Evidence map›Paper›PMID 39113025›Full record

ArticleCardiovascular diabetology2024

Predicting gestational diabetes mellitus risk at 11-13 weeks' gestation: the role of extrachromosomal circular DNA.

Jin Wang, Pengyu Huang, Fei Hou, Dongdong Hao, Wushan Li, Hua Jin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diabetology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Discovery and validation of GNA12Frontiers in neurology · 2026
    Article
  3. Extrachromosomal Circular DNA and Transposable Elements in Type 2 Diabetes.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jin Wang *Prenatal Diagnosis Center, Jinan Maternal and Child Health Care Hospital, No.2, Jianguo Xiaojing Roud, Jinan, 250002, Shandong Province, People's Republic of China.
Pengyu Huang *Fujian Provincial Sperm Bank, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, 350005, Fujian Province, People's Republic of China.
Fei HouPrenatal Diagnosis Center, Jinan Maternal and Child Health Care Hospital, No.2, Jianguo Xiaojing Roud, Jinan, 250002, Shandong Province, People's Republic of China.
Dongdong HaoDepartment of Family Planning, Jinan Maternal and Child Health Care Hospital, Jinan, Shandong Province, People's Republic of China.
Wushan LiDepartment of Obstetrics, Jinan Maternal and Child Health Care Hospital, Jinan, Shandong Province, People's Republic of China.
Hua JinPrenatal Diagnosis Center, Jinan Maternal and Child Health Care Hospital, No.2, Jianguo Xiaojing Roud, Jinan, 250002, Shandong Province, People's Republic of China. wangjinshiyi@126.com.

Funding

Joint Funds for the Innovation of Science and Technology, Fujian Province 2023Y9384Medical and Health Science and Technology Development Project of Shandong Province 202305020433Science and Technology Development Project of Jinan 202225064Science and Technology Development Project of Jinan 202328021
6 · The paper itself

Abstract

backgroundGestational diabetes mellitus (GDM) significantly impacts maternal and infant health both immediately and over the long term, yet effective early diagnostic biomarkers are currently lacking. Thus, it is essential to identify early diagnostic biomarkers for GDM risk screening. Extrachromosomal circular DNA (eccDNA), being more stable than linear DNA and involved in disease pathologies, is a viable biomarker candidate for diverse conditions. In this study, eccDNA biomarkers identified for early diagnosis and assessment of GDM risk were explored.

methodsUsing Circle-seq, we identified plasma eccDNA profiles in five pregnant women who later developed GDM and five matched healthy controls at 11-13 weeks of gestation. These profiles were subsequently analyzed through bioinformatics and validated through outward PCR combined with Sanger sequencing. Furthermore, candidate eccDNA was validated by quantitative PCR (qPCR) in a larger cohort of 70 women who developed GDM and 70 normal glucose-tolerant (NGT) subjects. A ROC curve assessed the eccDNA's diagnostic potential for GDM.

results2217 eccDNAs were differentially detected between future GDM patients and controls, with 1289 increased and 928 decreased in abundance. KEGG analysis linked eccDNA genes mainly to GDM-related pathways such as Rap1, MAPK, and PI3K-Akt, and Insulin resistance, among others. Validation confirmed a significant decrease in eccDNA PRDM16

conclusionsOur study first demonstrats that eccDNAs are aberrantly produced in women who develop GDM, including PRDM16

trial registrationChiCTR2300075971, http://www.chictr.org.cn . Registered 20 September 2023.

Indexed as

Diabetes, GestationalDNA, CircularGestational AgePredictive Value of TestsAdultBiomarkersCase-Control StudiesCell-Free Nucleic AcidsEarly DiagnosisFemaleHumansPregnancyPregnancy Trimester, FirstReproducibility of ResultsRisk AssessmentRisk FactorsBiomarkersCell-Free Nucleic AcidsDNA, CircularExtrachromosomal circular DNAGestational diabetes mellitusPredictive biomarker

Identifiers

PMID39113025
PMCPMC11304788

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.